ASN-008 is under clinical development by Formation Bio and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs for Pruritus have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ASN-008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASN-008 overview
ASN-008 is under development for the treatment of pruritis associated with atopic dermatitis (AD) and notalgia paresthetica. The drug candidate belongs to the class of aminoindane compounds that acts by targeting sodium ion channel. It is applied topically in the form of gel.
It was under development for the treatment of pain.
Formation Bio overview
Formation Bio is a clinical-stage pharmaceutical company that carries out drug development through tech-driven and AI-native platform. The company’s product pipeline include ASN008, Gusacitinib and Sprifermin. Its pipeline treats atopic dermatitis, chronic hand eczema and knee osteoarthritis. Formation Bio carries out platform such as patient intelligence and engagement data driven drug development and clinical data oversight. It also carries out research and development, IT solutions, automation and data-insights. Formation Bio is headquartered in New York, the US.
For a complete picture of ASN-008’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
